CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
CERo Therapeutics Holdings, Inc.
CERO THERAPEUTICS HOLDINGS, INC. (CERO) dilution facts from SEC filings
Snapshot as of Sep 30, 2026, built from 39 SEC filings.
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 8 warrant series recorded as outstanding
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.